GlassScriptPhysician profile
Brandy Locke
NPI 1235652678
$5,547.59
in general payments reported to CMS, 2019-2025
26 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,424 · 2022: $348 · 2023: $952 · 2024: $1,060 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,775.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,989.82 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $652.54 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.82 | 2021-2025 | Ofev, Stiolto Respimat |
| Viatris Specialty LLC | $242.06 | 2025 | Yupelri |
| Electromed, INC. | $232.68 | 2021-2025 | Smartvest |
| Axsome Therapeutics, INC. | $230.12 | 2024-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $223.91 | 2021-2025 | Opsumit, Opsynvi, Uptravi |
| United Therapeutics Corporation | $149.76 | 2021-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $116.80 | 2023-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $104.14 | 2021-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $102.92 | 2021-2024 | Dupixent |
| Inspire Medical Systems, INC. | $97.56 | 2023-2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $95.19 | 2021 | |
| Genzyme Corporation | $86.24 | 2025 | |
| Mallinckrodt Hospital Products INC. | $79.83 | 2021-2024 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $79.19 | 2023-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $69.07 | 2021-2025 | |
| Verona Pharma, INC. | $65.12 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $61.65 | 2021-2024 | Yupelri |
| Gilead Sciences, INC. | $54.89 | 2021 | |
| Harmony Biosciences LLC | $52.17 | 2023-2024 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $43.10 | 2024-2025 | Lumryz |
| Baxter Healthcare | $36.91 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $33.69 | 2025 | Brinsupri, Arikayce |
| Novo Nordisk INC | $18.50 | 2025 | Wegovy |
| Philips North America LLC | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Locke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.